All In Biotech

Drug Trial Radar · NCT07920861

A Study of HB0017 Injection in Healthy Volunteers to Evaluate Safety and Tolerability of a Single Subcutaneous Injection in Low-Body-Weight Subjects; and Pharmacokinetics at Different Subcutaneous Injection Sites at the Same Dose

A Study of HB0017 Injection to Investigate PK After Subcutaneous Administration at Different Injection Sites in Healthy Volunteers, and to Evaluate Its Safety, Tolerability, and Pharmacokinetics in Low-body-weight Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Jan 19, 2026

Primary completion

Dec 31, 2026

Study completion Feb 28, 2027

Sponsor

Lead sponsor
Huabo Biopharm Co., Ltd.Industry
Sponsor type
Industry
Collaborators
Shanghai Huaota Biopharmaceutical Co., Ltd.
First posted
Nov 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to (PART 1) to evaluate the safety and tolerability of a single subcutaneous injection of HB0017 Injection in healthy subjects with low body weight; ( PART 2) to compare the pharmacokinetics (PK) of HB0017 following single subcutaneous administration at different injection sites at the same dose.

Conditions

  • Psoriasis
  • Ankylosing Spondylitis

Interventions

  • HB0017 InjectionBiological

    pre-filled syringe, 150 mg/(1 mL)/per injection

  • HB0017 PlaceboOther

    pre-filled syringe,1 mL/per injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse eventsTime frame: through study completion
  2. CmaxTime frame: From pre-dosing to 140 days post-dosing
  3. AUCinfTime frame: From pre-dosing to 140 days post-dosing

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • First People's Hospital of Hangzhou

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.